Business
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Product Revenues and Outlines 2022 Objectives
- Unaudited Net Product Revenues of Approximately $29.7 Million for Fourth Quarter 2021 and Approximately $98.3 Million for the Full Year 2021- - Company on
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"- Unaudited Net Product Revenues of Approximately $29.7 Million for Fourth Quarter 2021 and Approximately $98.3 Million for the Full Year 2021-\n - Company on Track to Announce Top-Line Phase 3 Data from SIENDO Study Evaluating XPOVIO® (selinexor) in Patients with Endometrial Cancer in First Quarter 2022 -\n\n\nNEWTON, Mass., Jan. 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2021 net product revenue estimates for XPOVIO, the Company's first-in-class, oral XPO1 inhibitor, and outlined its 2021 achievements and 2022 objectives.\nBased on preliminary unaudited financial information, Karyopharm expects net product revenues of XPOVIO to be approximately $29.7 million for the fourth quarter and approximately $98.3 million for the full year 2021. \n\"For 2022, we are focused on making significant advances across our pipeline, beginning with top-line results from the Phase 3 SIENDO study evaluating selinexor as a maintenance therapy following front-line chemotherapy in patients with advanced or metastatic endometrial cancer, which remain on track to be reported this quarter,\" said Richard Paulson, President and Chief Executive Officer of Karyopharm. \"Building on the strong revenue growth in the second half of 2021, we will continue to prioritize driving sales and the adoption of XPOVIO in multiple myeloma. I am extremely pleased with the continued progress of our pipeline in key additional indications of multiple myeloma, myelodysplastic syndromes and myelofibrosis and our ability to further expand our impact on patients globally with our recent partnership with Menarini.\"\nKey Program Achievements in 2021\nSelinexor in Multiple Myeloma \nLaunched XPOVIO in the U.S. in second line multiple myeloma and strengthened the commercial team, resulting in continued strong net product revenue growth. Generated compelling clinical data supporting selinexor's efficacy, durability and tolerability when combined with the approved agents Velcade® (bortezomib), Pomalyst® (pomalidomide) or Kyprolis® (carfilzomib) in patients who have been previously exposed to anti-CD38 monoclonal antibody treatment, where there is a substantial unmet need for a new class of therapy. These results we...